Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity-Reference-Cited by-同舟云学术

Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity

Published:2020-06-16 Issue:9 Volume:16 Page:2165-2175
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Schultheis Katherine¹,Pugh Holly M¹,Oh Janet¹,Nguyen Jacklyn¹,Yung Bryan¹,Reed Charles¹,Cooch Neil¹,Chen Jing¹,Yan Jian¹,Muthumani Kar²,Humeau Laurent M.¹,Weiner David B.²,Broderick Kate E.¹,Smith Trevor R. F.¹

Affiliation:

1. Inovio Pharmaceuticals, Plymouth Meeting, PA, USA

2. Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1748979

Reference53 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

2. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis